3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lymphoma
68
Lymphoma, Non-Hodgkin
53
Lymphoma, Large B-Cell, Diffuse
47
Hodgkin Disease
42
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Leukemia, Myeloid, Acute
41
Small Cell Lung Carcinoma
37
Leukemia
37
Burkitt Lymphoma
32
Lymphoma, Mantle-Cell
29
Lymphoma, Follicular
28
Lung Neoplasms
20
Carcinoma, Non-Small-Cell Lung
20
Multiple Myeloma
19
Congenital Abnormalities
18
Lymphoma, Large-Cell, Immunoblastic
17
Lymphoma, Large-Cell, Anaplastic
17
Recurrence
15
Lymphoma, B-Cell, Marginal Zone
15
Lymphoma, B-Cell
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Neuroblastoma
13
Neoplasms
13
Myelodysplastic Syndromes
11
Waldenstrom Macroglobulinemia
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma, T-Cell
10
Immunoblastic Lymphadenopathy
10
Sarcoma
9
Myeloproliferative Disorders
9
Interventions
Carboplatin
6
Paclitaxel
5
Taxes
3
Docetaxel
3
Cisplatin
3
Gemcitabine
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Bevacizumab
2
talimogene laherparepvec
1
saracatinib
1
romidepsin
1
rilotumumab
1
ganitumab
1
Zoledronic Acid
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
Therapeutics
1
Talc
1
Surveys and Questionnaires
1
Spectrum Analysis
1
Sodium Chloride
1
Pemetrexed
1
Nivolumab
1
Metformin
1
Magnetic Resonance Spectroscopy
1
Immunohistochemistry
1
Imatinib Mesylate
1
Gefitinib
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pleural Effusion, Malignant
×
Etoposide
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts